Clinical Features and Univariate Analyses of Prognostic Covariates in Study Subjects (n = 55)
| Feature | No. of patients | No. of deaths (%) | OS (%) [95% CI] | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 mo | 12 mo | 24 mo | P value* | ||||||
| Initial FIGO stage | |||||||||
| IB–IIA | 25 | 5 (20.0) | 96.0 [88.3–100] | 79.5 [61.2–97.8] | 70.7 [47.6–93.7] | 0.1184 | |||
| IIB–IVA | 30 | 13 (43.3) | 88.5 [76.2–100] | 62.1 [40.8–83.4] | 13.6 [0–36.1] | ||||
| Histopathology | |||||||||
| SCC | 44 | 17 (38.6) | 90.2 [8.10–99.3] | 63.2 [46.2–80.3] | 28.3 [5.0–51.6] | 0.1259 | |||
| Adeno-adenosquamous | 11 | 1 (9.1) | 100 [—] | 100 [—] | 100 [—] | ||||
| Differentiation | |||||||||
| Well or moderate | 34 | 12 (35.3) | 90.9 [81.0–100] | 90.9 [81.0–100] | 33.0 [5.4–60.6] | 0.8392 | |||
| Poor | 21 | 6 (28.6) | 94.4 [83.9–100] | 94.4 [83.9–100] | 22.9 [0–60.5] | ||||
| Primary treatment | |||||||||
| Radical surgery | 20 | 2 (10.0) | 100 [—] | 93.3 [80.7–100] | 77.8 [48.0–100] | 0.0081 | |||
| RT | 35 | 16 (45.7) | 87.6 [76.2–99.0] | 56.3 [36.2–76.4] | 12.3 [0–32.8] | ||||
| Pelvic node metastasis before primary treatment | |||||||||
| Negative | 23 | 5 (21.7) | 100 [—] | 91.3 [79.8–100] | 86.1 [71.4–100] | 0.0585 | |||
| Positive | 32 | 13 (40.6) | 100 [—] | 93.3 [84.4–100] | 51.4 [29.5–73.4] | ||||
| Symptoms | |||||||||
| Symptomatic | 18 | 8 (44.4) | 75.6 [54.8–96.5] | 57.6 [30.6–84.7] | 21.7 [0–55.6] | 0.0536 | |||
| Asymptomatic | 37 | 10 (27.0) | 100 [—] | 76.5 [59.9–93.1] | 31.1 [0–62.9] | ||||
| SCC-Ag† (ng/mL) | |||||||||
| ≤4 | 26 | 3 (11.5) | 95.5 [86.6–100] | 88.6 [73.4–100] | 59.1 [10.8–100] | 0.0041 | |||
| >4 | 26 | 14 (53.8) | 88.1 [75.5–100] | 48.5 [25.4–71.6] | 11.1 [0–30.5] | ||||
| Locations of recurrences | |||||||||
| Central or pelvic | 11 | 4 (36.4) | 100 [—] | 74.1 [42.5–100] | 37.0 [0–90.7] | 0.6951 | |||
| Distant | 27 | 6 (22.2) | 96.3 [89.2–100] | 75.8 [54.2–97.3] | 32.5 [0–79.4] | ||||
| Pelvic and distant | 17 | 8 (47) | 80.4 [60.4–100] | 58.4 [32.8–84.1] | 36.5 [7.3–65.8] | ||||
| Salvage treatment‡ | |||||||||
| Curative intent | 28 | 6 (21.4) | 96.4 [89.6–100] | 81.3 [64.4–98.3] | 48.8 [12.4–85.1] | 0.0642 | |||
| Surgery§ | 13 | 5 (38.5) | 91.7 [76.0–100] | 60.2 [21.3–99.0] | 0 [—] | ||||
| CCRT | 15 | 1 (6.7) | 100 [—] | 90.0 [71.4–100] | 90.0 [71.4–100] | ||||
| Curative: no change | 19 | 6 (31.6) | 94.7 [84.7–100] | 74.8 [53.2–95.4] | 37.4 [0–75.6] | 0.372 | |||
| Curative: modified | 9 | 0 (0) | 100 [—] | 100 [—] | 100 [—] | ||||
| Palliation | 27 | 12 (44.4) | 88.6 [76.4–100] | 65.6 [45.9–85.3] | 27.8 [0–56.9] | ||||
SCC = squamous cell carcinoma; CCRT = concurrent chemoradiation therapy.
↵* P values were determined using log-rank test.
↵† SCC-Ag levels were the value of at time of recurrence. Three patients were unavailable due to elevation of CEA.
↵‡ Difference (P = 0.0249) was not significant with Bonferroni correction for multiple comparisons.
↵§ Surgery consisted of paraaortic, neck, or inguinal lymph excision, radical hysterectomy, or pelvic exenteration. Adjuvant therapy consisted of intraoperative RT chemoradiation or RT to previously unradiated sites, postoperative adjuvant chemotherapy, or postoperative chemoradiation or RT to previously unradiated sites.